Vir Biotechnology Inc (VIR)
Receivables turnover
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 86,180 | 118,803 | 490,721 | 444,237 | 1,613,740 | 2,377,077 | 2,106,136 | 2,325,891 | 1,095,407 | 284,394 | 182,706 | 72,626 | 76,368 | 75,614 | 75,089 | |||
| Receivables | US$ in thousands | — | — | — | — | — | — | 7,000 | 1,223,160 | 773,079 | 93,003 | — | 112,500 | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | — | 300.88 | 1.90 | 1.42 | 3.06 | — | 0.65 | — | — | — |
December 31, 2023 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $86,180K ÷ $—K
= —
The receivables turnover ratio for Vir Biotechnology Inc improved significantly from Q1 2022 to Q2 2022, with a notable increase from 1.90 to 301.17. This substantial jump in the ratio indicates that the company was able to collect its accounts receivable much more efficiently in Q2 2022 compared to the previous quarter. However, it's important to note that there is missing data for subsequent quarters, which hinders a comprehensive analysis of the receivables turnover trend beyond Q2 2022. Further information would be needed to assess the consistency and sustainability of this improved performance in managing receivables.
Peer comparison
Dec 31, 2023